Valuation : CSL Limited

Market Cap 59.05B 50.93B 47.91B 43.65B 82.08B 5,604B 82.52B 566B 220B 2,851B 222B 217B 9,452B P/E 2027 *
20.2x
P/E 2028 * 18.4x
Enterprise Value 67.92B 58.59B 55.11B 50.21B 94.42B 6,446B 94.93B 652B 254B 3,279B 255B 249B 10,873B EV / Sales 2027 *
4.31x
EV / Sales 2028 * 4.14x
Free-Float
99.97%
Yield 2027 *
2.44%
Yield 2028 * 2.59%
1 day+0.68%
1 week+0.60%
Current month+1.11%
1 month+39.57%
3 months+87.42%
6 months+17.77%
Current year+0.48%
1 week 170.75
Extreme 170.75
175.36
1 month 121.87
Extreme 121.87
175.97
Current year 90
Extreme 90
184.62
1 year 90
Extreme 90
222.47
3 years 90
Extreme 90
313.55
5 years 90
Extreme 90
319.78
10 years 90
Extreme 90
342.75
Manager TitleAgeSince
Chief Executive Officer 63 2026-02-10
Director of Finance/CFO 52 2025-10-06
Chief Operating Officer - 2025-04-30
Director TitleAgeSince
Director/Board Member 72 2018-10-16
Director/Board Member 70 2011-02-01
Director/Board Member 71 2019-12-08
Date Insider Type Main position Quantity % Market Cap. Importance
8/21/26 Exercice

Director

152 0.0000%
8/21/26 Exercice

Director

244 0.0001%
8/21/26 Exercice

Director

-183 0.0000%
Change 5-day change 1-year change 3-year change Capi.($)
+0.60%+0.60%-16.74%-35.37% 59.05B
+3.10%-1.17%+41.87%-0.94% 82.26B
+9.93%-2.87%+540.39%+37.06% 61.59B
+0.13%-4.10%-0.74%+34.87% 51.23B
+1.49%-2.50%+9.69%+163.06% 48.3B
-0.28%-2.14%+63.39%-19.14% 31.92B
+1.45%-3.63%+47.75%+93.24% 25.34B
-0.39%-7.74%-3.80%+193.62% 22.56B
+1.69%-2.60%+61.63%+116.78% 16.56B
-2.11%-1.47%-14.00%+794.40% 15.28B
Average +1.58%-2.50%+72.94%+137.76% 41.41B
Weighted average by Cap. +2.42%-2.68%+96.89%+72.37%

Financials

2027 *2028 *
Net sales 15.75B 13.58B 12.78B 11.64B 21.89B 1,494B 22.01B 151B 58.79B 760B 59.12B 57.84B 2,521B 16.28B 14.05B 13.21B 12.04B 22.64B 1,545B 22.76B 156B 60.8B 786B 61.14B 59.81B 2,607B
Net income 2.83B 2.44B 2.3B 2.09B 3.94B 269B 3.96B 27.18B 10.58B 137B 10.64B 10.41B 454B 3.16B 2.73B 2.57B 2.34B 4.4B 300B 4.42B 30.33B 11.81B 153B 11.87B 11.61B 506B
Net Debt 8.88B 7.66B 7.2B 6.56B 12.34B 843B 12.41B 85.16B 33.15B 429B 33.33B 32.61B 1,421B 8.38B 7.23B 6.8B 6.2B 11.65B 795B 11.71B 80.39B 31.29B 405B 31.46B 30.78B 1,342B
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
29,000
Date Price Change Volume
26-09-02 A$173.41 +0.64% 446,658
26-09-01 A$172.31 +0.43% 1,501,636
26-08-31 A$171.57 -0.44% 1,673,346
26-08-28 A$172.32 -0.90% 1,158,131
26-08-27 A$173.88 +0.84% 874,276
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
123.29USD
Average target price
118.97USD
Spread / Average Target
-3.50%

Quarterly revenue - Rate of surprise